[Expression and Clinical Significance of SOCS1 and SOCS3 in Myelodysplastic Syndrome]

To investigate the expression levels of suppressor of cytokine signaling 1 ( SOCS1) and 3 (SOCS3) in patients with myelodysplastic syndrome (MDS) and assess their clinical significance.

A total of 74 MDS patients were included in our hospital from January 2020 to June 2022, and 56 patients with non-malignant hematological diseases were selected as control group. The mRNA expression levels of SOCS1 and SOCS3 in bone marrow mononuclear cells were measured using real-time quantitative PCR, and their relationship with clinical characteristics of MDS patients was analyzed to evaluate their value in assessing treatment outcomes and prognosis.

The mRNA expression levels of SOCS1 and SOCS3 in MDS patients were significantly lower than those in the control group (both P <0.01). There were certain differences in mRNA expression of SOCS1 and SOCS3 among different MDS subtypes, with patients in the MDS-EB group showing significantly lower expression than those in the MDS-SLD group (both P <0.05). Additionally, patients classified as relatively high-risk according to the IPSS-R prognosis risk stratification had significantly lower expression of SOCS1 and SOCS3 compared to the relatively low-risk group (both P <0.01). The patients with low expression of SOCS1 and SOCS3 had a lower overall survival rate, while with a higher proportion of progression to acute myeloid leukemia. The Cox regression analysis also indicated that SOCS1 has high predictive value for poor prognosis in MDS patients.

Both SOCS1 and SOCS3 mRNA expression are significantly reduced in MDS and closely related to poor prognosis, which can be of great value for disease prediction and prognosis.